<DOC>
	<DOCNO>NCT00006055</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether prompt engraftment autologous peripheral blood stem cell transplantation use filgrastim ( G-CSF ) mobilization patient life threaten autoimmune disease . II . Determine kinetics T- B-cell immune reconstitution combination time plasmapheresis , high dose cyclophosphamide total lymphoid irradiation , posttransplant immunosuppression cyclosporine patient . III . Determine whether treatment regimen beneficially influence clinical course patient .</brief_summary>
	<brief_title>Autologous Peripheral Blood Stem Cell Transplantation Patients With Life Threatening Autoimmune Diseases</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive filgrastim ( G-CSF ) SC daily peripheral blood stem cell ( PBSC ) collect . On fifth day G-CSF therapy , PBSC collect . Patients undergo plasmapheresis day -9 -7 . Patients receive cyclophosphamide IV day -6 -3 total lymphoid irradiation day -1 . PBSC reinfused day 0 . Following PBSC reinfusion , patient receive prophylaxis oral prednisone methylprednisolone IV day -1 28 , antithymocyte globulin IV day 1-3 , cyclosporine every 12 hour day 1-60 . Patients autoimmune thrombocytopenia purpura , autoimmune hemolytic anemia , pure red cell aplasia follow day 7 , 14 , 21 , 28 , 60 , 100 , 6 month , 1 , 2 , 5 year . Patients rheumatoid arthritis , juvenile rheumatoid arthritis , systemic lupus erythematosus follow day 14 , 28 , 60 , 100 , every 6 month . Patients vasculitis monitor abnormal clinical laboratory parameter characteristic individual type vasculitis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Red-Cell Aplasia , Pure</mesh_term>
	<mesh_term>Purpura , Schoenlein-Henoch</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Takayasu Arteritis</mesh_term>
	<mesh_term>Aortic Arch Syndromes</mesh_term>
	<mesh_term>Polyarteritis Nodosa</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Vasculitis , Leukocytoclastic , Cutaneous</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Autoimmune thrombocytopenia purpura : platelet count le 20,000/mm3 Adequate increase marrow megakaryocyte Presence detectable platelet associate immunoglobulin due alloreactive antibody posttransfusion purpura Prior response immunosuppressive therapy Platelet count chronically le 20,000/mm3 petechial bleeding le 50,000/mm3 bleeding OR Any history life threaten hemorrhage Refractory conventional therapy least 21 day Splenectomy At least 1 additional immunosuppressive therapy apply splenectomy OR Controlled conventional therapy price unacceptable toxicity : Serious steroid relate toxicity Absolute neutrophil count less 500/mm3 25 % time , pure red blood cell transfusion dependent toxicity ( e.g. , hemorrhagic cystitis ) consequence chronic cytotoxic therapy Unable wean chronic daily intermittent cytotoxic therapy Autoimmune hemolytic anemia pure red cell aplasia , AIHA : Hemolytic anemia Hemoglobin le 10.0 g/dL without transfusion Hemolysis evidence : Sustained reticulocytosis ( great 125,000/mm3 ) without evidence active bleeding increase hemoglobin Laboratory evidence hemolysis Positive direct antiglobulin test equivalent immune adherence test No evidence paroxysmal nocturnal hemoglobinuria Negative Ham 's test sucrose hemolysis . For PRCA : Anemia due selective decrease marrow erythroid precursor Hemoglobin le 10.0 g/dL without transfusion Severe reticulocytopenia ( le 20,000/mm3 despite anemia ) Severely decreased marrow erythroid precursor Positive marrow coculture serum cell response immunosuppression No evidence PNH Negative Ham 's test sucrose hemolysis Severe disease : Chronic ( i.e. , great 1 year ) Transfusion dependent untransfused hemoglobin le 8.0 g/dL Ferritin great 2,000 evidence organ dysfunction due iron overload Refractory conventional therapy 3 following : High dose steroid ( least 1 mg/kg ) least 21 day Splenectomy ( except cold reactive antibody ) 1 additional immunosuppressive therapy OR Controlled conventional therapy price unacceptable toxicity Rheumatoid arthritis : Morning stiffness least 6 week Arthritis 3 joint area Arthritis hand joint Symmetric arthritis Rheumatoid nodules Serum rheumatoid factor Radiographic change Active rheumatoid disease evidence follow : Elevated Westergren erythrocyte sedimentation rate Minimum 16 swollen tender joint use 28 joint count method Must high risk develop deform joint disease define least 2 follow : High titer IgMIgG rheumatoid factor Radiographic evidence erosive arthritis develop within first 24 month clinical disease Functional class II III Refractory conventional therapy 12 month : Methotrexate use combination cyclosporine , hydroxychloroquine , sulfasalazine OR Intramuscular gold therapy ( total dose great 1.0 g duration least 6 month ) OR Controlled conventional therapy price unacceptable toxicity Juvenile rheumatoid arthritis : Under 16 year age onset Arthritis 1 joint define swell effusion , presence 2 following : Limitation range motion Tenderness pain motion Increased heat Duration disease 6 week longer Onset type define type disease first 6 month : Polyarthritis ( i.e. , 5 inflamed joint ) Oligoarthritis ( i.e. , less 5 inflamed joint ) Systemic ( i.e. , arthritis characteristic fever ) Exclusion form juvenile arthritis Active disease evidence 1 following : Minimum 2 swollen tender joint use 71 joint count method Endocardial myocardial disease , serositis Anemia thrombocytosis chronic disease High risk develop deform joint disease evidence potential life threaten involvement least 1 internal organ system Radiographic evidence erosive arthritis develop within first 24 month clinical disease Functional class II III Endocardial , myocardial , pericardial , and/or pleural disease Hemoglobin le 10.0 g/dL platelet count great 600,000/mm3 Refractory conventional therapy 12 month methotrexate use combination hydroxychloroquine , sulfasalazine , azathioprine , cyclosporine , cyclophosphamide OR Controlled conventional therapy price unacceptable toxicity Systemic lupus erythematosus : Malar rash Discoid rash Photosensitivity Oral ulcer Arthritis Serositis Renal disorder Neurologic disorder Hematologic disorder Immunologic disorder Antinuclear antibody Must least 4 7 variable lupus activity scale measure Evidence potential life threaten involvement least 1 internal organ system Endocardial and/or myocardial disease Central nervous system disease Pulmonary parenchymal disease Renal disease define WHO III , IV V high activity low chronicity index Immune mediate cytopenias Refractory conventional therapy attempt control disease least 2 drug , include prednisone 1 following : Azathioprine Cyclophosphamide ( great 500 mg/m2 monthly 6 month ) Cyclosporine OR Controlled conventional therapy price unacceptable toxicity Vasculitis Definitive diagnosis 1 follow form : ChurgStrauss syndrome Giant cell arteritis HenochSchonlein purpura Hypersensitivity vasculitis Polyarteritis nodosa Takayasu arteritis Wegener 's granulomatosis Evidence active disease define reversible manifestation underlie inflammatory process Must 1 following : Elevated Westergren erythrocyte sedimentation rate Elevated C reactive protein Decrease serum complement level Evidence potential life threaten involvement least 1 internal organ system Endocardial and/or myocardial disease Central nervous system disease Pulmonary parenchymal disease Renal disease define WHO III , IV V high activity low chronicity index Immune mediate cytopenias Refractory conventional therapy ( i.e. , fail relapse within 6 month ) attempt control disease least 2 drug , include prednisone 1 following : Methotrexate Azathioprine Cyclophosphamide Cyclosporine OR Controlled conventional therapy price unacceptable toxicity Performance status : ECOG 01 ECOG 2 allow provide symptom directly relate autoimmune disease Hepatic : No history severe , prior ongoing chronic liver disease Bilirubin le 2.0 mg/dL AST le 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN Renal : Creatinine le 2.5 mg/dL OR Creatinine great 2 time normal baseline age pediatric patient Cardiovascular : No symptom cardiac disease No active ischemic heart disease Ejection fraction great 45 % MUGA No uncontrolled hypertension Pulmonary : FEV1/FVC least 60 % OR Resting PO2 least 80 mm Hg DLCO great 50 % predict O2 saturation great 94 % child unable perform PFTs Neurologic : No active ongoing ischemic degenerative CNS disease attributable underlying disease Other : Not pregnant No poorly control diabetes HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>Churg-Strauss syndrome</keyword>
	<keyword>Schonlein-Henoch purpura</keyword>
	<keyword>Takayasu arteritis</keyword>
	<keyword>Wegener 's granulomatosis</keyword>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>autoimmune hemolytic anemia</keyword>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>giant cell arteritis</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>hypersensitivity vasculitis</keyword>
	<keyword>immune thrombocytopenic purpura</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>juvenile rheumatoid arthritis</keyword>
	<keyword>polyarteritis nodosa</keyword>
	<keyword>pure red cell aplasia</keyword>
	<keyword>rare disease</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>vasculitis</keyword>
</DOC>